Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NBT508
- Development stage
- Unknown
- Lead developer
- New-Bio
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NBT508 is a recombinant humanized bispecific antibody targeting CD20 and CD3, developed by Newport Biopharmaceutical Technology (Shanghai) Co., Ltd. for the treatment of B-cell non-Hodgkin lymphoma (B-NHL). By simultaneously binding to the CD20 antigen on the surface of malignant B cells and the CD3 receptor on T cells, NBT508 facilitates the formation of an immunological synapse, leading to T-cell activation and the subsequent directed lysis of the cancerous B cells. It is currently undergoing Phase 1 clinical evaluation in patients with relapsed or refractory B-cell malignancies.
02
Targets
B-cell antigen receptor complex-associated protein beta chainTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on NBT508.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NBT508.